Wave Life Sciences Ltd. - Ordinary Shares (WVE) News
Filter WVE News Items
WVE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
WVE News Highlights
- For WVE, its 30 day story count is now at 24.
- Over the past 22 days, the trend for WVE's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about WVE are WAVE, PTE and CNS.
Latest WVE News From Around the Web
Below are the latest news stories about Wave Life Sciences Ltd that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Wave Life Sciences Ltd. 2021 Q3 - Results - Earnings Call PresentationThe following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2021 Q3 earnings call.... |
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2021 Results - Earnings Call TranscriptWave Life Sciences Ltd. (WVE) Q3 2021 Earnings Conference Call Nov 10, 2021 08:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President & Chief Executive Officer Chandra Vargeese - Chief Technology Officer Mike Panzara - Chief Medical Officer, Head of Therapeutics Discovery &... |
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue EstimatesWave Life Sciences (WVE) delivered earnings and revenue surprises of 81.25% and 240.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? |
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business UpdateStrengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly specific RNA editing and restoration of functional AAT protein substantially above therapeutic threshold; potential for best-in-class, potent and durable RNA editing in vivo in multiple preclinical models and tissues Dosing ongoing in three clinical programs (WVE-004, WVE-003, WVE-N531); data being ge |
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare ConferenceCAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 10:00 a.m. ET. A live webcast of the presentation wil |
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, November 10, 2021, to discuss its third quarter 2021 financial results and provide a business update. |
Will Wave Life Sciences (WVE) Report Negative Q3 Earnings? What You Should KnowWave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Zacks: Analysts Anticipate Wave Life Sciences Ltd. (NASDAQ:WVE) to Announce -$0.64 Earnings Per ShareEquities analysts expect Wave Life Sciences Ltd. (NASDAQ:WVE) to post earnings per share (EPS) of ($0.64) for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Wave Life Sciences earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.26). Wave Life Sciences posted earnings of ($0.86) per share during the [] |
Wave Life Sciences Ltd. (NASDAQ:WVE) Expected to Post Quarterly Sales of $10.70 MillionWall Street analysts forecast that Wave Life Sciences Ltd. (NASDAQ:WVE) will post $10.70 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Wave Life Sciences earnings, with the lowest sales estimate coming in at $3.50 million and the highest estimate coming in at $25.00 million. Wave Life Sciences [] |
Wave Life Sciences Ltd. (NASDAQ:WVE) Expected to Announce Quarterly Sales of $10.70 MillionEquities analysts expect Wave Life Sciences Ltd. (NASDAQ:WVE) to announce sales of $10.70 million for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Wave Life Sciences earnings, with the highest sales estimate coming in at $25.00 million and the lowest estimate coming in at $3.50 million. Wave Life Sciences [] |